archive-july-2026
Mercks & Co's sprint against the KEYTRUDA patent cliff: will it cross the finish line?
Merck quietly became one of the most aggressive external innovation buyers in the industry. But when your entire strategy hinges on replacing a $25B drug before the patent clock runs out, is buying your pipeline fast enough? Read the mechanics of what Merck & Co is doing to avoid the fall.